company background image
LOVE

Cannara BiotechTSXV:LOVE Stock Report

Market Cap

CA$131.5m

7D

-6.3%

1Y

57.9%

Updated

23 Sep, 2021

Data

Company Financials
LOVE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

LOVE Overview

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada.

Cannara Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cannara Biotech
Historical stock prices
Current Share PriceCA$0.15
52 Week HighCA$0.075
52 Week LowCA$0.18
Beta1.89
1 Month Change-11.77%
3 Month Change-11.77%
1 Year Change57.90%
3 Year Changen/a
5 Year Changen/a
Change since IPO-50.82%

Recent News & Updates

Shareholder Returns

LOVECA PharmaceuticalsCA Market
7D-6.3%-0.1%-1.0%
1Y57.9%40.5%31.4%

Return vs Industry: LOVE exceeded the Canadian Pharmaceuticals industry which returned 37.4% over the past year.

Return vs Market: LOVE exceeded the Canadian Market which returned 32.3% over the past year.

Price Volatility

Is LOVE's price volatile compared to industry and market?
LOVE volatility
LOVE Beta1.89
Industry Beta1.84
Market Beta1

Stable Share Price: LOVE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: LOVE's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aZohar Krivorothttps://cannara.ca

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Montreal, Canada.

Cannara Biotech Fundamentals Summary

How do Cannara Biotech's earnings and revenue compare to its market cap?
LOVE fundamental statistics
Market CapCA$131.47m
Earnings (TTM)-CA$6.52m
Revenue (TTM)CA$11.37m

11.6x

P/S Ratio

-20.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LOVE income statement (TTM)
RevenueCA$11.37m
Cost of RevenueCA$5.81m
Gross ProfitCA$5.56m
ExpensesCA$12.08m
Earnings-CA$6.52m

Last Reported Earnings

May 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0089
Gross Margin48.86%
Net Profit Margin-57.34%
Debt/Equity Ratio44.0%

How did LOVE perform over the long term?

See historical performance and comparison

Valuation

Is Cannara Biotech undervalued compared to its fair value and its price relative to the market?

3.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LOVE is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.

PE vs Market: LOVE is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LOVE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LOVE is overvalued based on its PB Ratio (3.6x) compared to the CA Pharmaceuticals industry average (2.6x).


Future Growth

How is Cannara Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

44.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannara Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cannara Biotech performed over the past 5 years?

46.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: LOVE is currently unprofitable.

Growing Profit Margin: LOVE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LOVE's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare LOVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LOVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).


Return on Equity

High ROE: LOVE has a negative Return on Equity (-18%), as it is currently unprofitable.


Financial Health

How is Cannara Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: LOVE's short term assets (CA$13.9M) exceed its short term liabilities (CA$4.7M).

Long Term Liabilities: LOVE's short term assets (CA$13.9M) do not cover its long term liabilities (CA$16.7M).


Debt to Equity History and Analysis

Debt Level: LOVE's debt to equity ratio (44%) is considered high.

Reducing Debt: Insufficient data to determine if LOVE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LOVE has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: LOVE is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is Cannara Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LOVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LOVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LOVE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LOVE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LOVE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Zohar Krivorot (44 yo)

no data

Tenure

CA$92,307

Compensation

Mr. Zohar Krivorot is Founder, President, Chief Executive Officer and Director at Cannara Biotech Inc. since December 31, 2018 and also serves as its Chairman. A successful entrepreneur, Mr. Krivorot has f...


CEO Compensation Analysis

Compensation vs Market: Zohar's total compensation ($USD72.84K) is below average for companies of similar size in the Canadian market ($USD161.20K).

Compensation vs Earnings: Zohar's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: LOVE's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: LOVE's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LOVE insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.


Top Shareholders

Company Information

Cannara Biotech Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cannara Biotech Inc.
  • Ticker: LOVE
  • Exchange: TSXV
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$131.472m
  • Shares outstanding: 876.48m
  • Website: https://cannara.ca

Number of Employees


Location

  • Cannara Biotech Inc.
  • 333 Decarie boulevard
  • Suite 200
  • Montreal
  • Quebec
  • H4N 3M9
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 23:09
End of Day Share Price2021/09/23 00:00
Earnings2021/05/31
Annual Earnings2020/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.